AU2018248425B2 - Methods and compositions for treating retina-associated disease using CCR3-inhibitors - Google Patents

Methods and compositions for treating retina-associated disease using CCR3-inhibitors Download PDF

Info

Publication number
AU2018248425B2
AU2018248425B2 AU2018248425A AU2018248425A AU2018248425B2 AU 2018248425 B2 AU2018248425 B2 AU 2018248425B2 AU 2018248425 A AU2018248425 A AU 2018248425A AU 2018248425 A AU2018248425 A AU 2018248425A AU 2018248425 B2 AU2018248425 B2 AU 2018248425B2
Authority
AU
Australia
Prior art keywords
alkyl
group
optionally substituted
formula
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018248425A
Other languages
English (en)
Other versions
AU2018248425A1 (en
Inventor
Laura CORADINI
Sam Jackson
Karoly Nikolich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkahest Inc
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of AU2018248425A1 publication Critical patent/AU2018248425A1/en
Application granted granted Critical
Publication of AU2018248425B2 publication Critical patent/AU2018248425B2/en
Priority to AU2024204133A priority Critical patent/AU2024204133B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2018248425A 2017-04-05 2018-04-04 Methods and compositions for treating retina-associated disease using CCR3-inhibitors Active AU2018248425B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024204133A AU2024204133B2 (en) 2017-04-05 2024-06-18 Methods and Compositions for Treating Retina-Associated Disease Using CCR3-Inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482134P 2017-04-05 2017-04-05
US62/482,134 2017-04-05
PCT/US2018/026091 WO2018187473A1 (en) 2017-04-05 2018-04-04 Methods and compositions for treating retina-associated disease using ccr3-inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024204133A Division AU2024204133B2 (en) 2017-04-05 2024-06-18 Methods and Compositions for Treating Retina-Associated Disease Using CCR3-Inhibitors

Publications (2)

Publication Number Publication Date
AU2018248425A1 AU2018248425A1 (en) 2019-10-31
AU2018248425B2 true AU2018248425B2 (en) 2024-03-28

Family

ID=62067800

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018248425A Active AU2018248425B2 (en) 2017-04-05 2018-04-04 Methods and compositions for treating retina-associated disease using CCR3-inhibitors
AU2024204133A Active AU2024204133B2 (en) 2017-04-05 2024-06-18 Methods and Compositions for Treating Retina-Associated Disease Using CCR3-Inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024204133A Active AU2024204133B2 (en) 2017-04-05 2024-06-18 Methods and Compositions for Treating Retina-Associated Disease Using CCR3-Inhibitors

Country Status (20)

Country Link
US (2) US11590118B2 (https=)
EP (2) EP3606521B1 (https=)
JP (1) JP7179755B2 (https=)
KR (1) KR102658724B1 (https=)
CN (1) CN110650740A (https=)
AU (2) AU2018248425B2 (https=)
BR (1) BR112019020430A2 (https=)
CA (1) CA3058654A1 (https=)
CL (1) CL2019002839A1 (https=)
CO (1) CO2019012336A2 (https=)
EA (1) EA201992356A1 (https=)
ES (2) ES2950453T3 (https=)
IL (1) IL269743B (https=)
MX (1) MX394915B (https=)
MY (1) MY199462A (https=)
NZ (1) NZ757769A (https=)
SG (1) SG11201909207VA (https=)
TW (1) TW201841636A (https=)
UA (1) UA125658C2 (https=)
WO (1) WO2018187473A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909245PA (en) * 2017-04-05 2019-11-28 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
CN112789044A (zh) * 2018-09-26 2021-05-11 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
AU2021287906B2 (en) * 2020-06-11 2025-09-11 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
CN112322719A (zh) * 2020-11-06 2021-02-05 温州医科大学 循环血外泌体miRNA作为视网膜静脉阻塞疾病诊断标志物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists
WO2013149987A1 (en) * 2012-04-04 2013-10-10 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising ccr3 antagonists
WO2013149986A1 (en) * 2012-04-03 2013-10-10 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002112800A (ru) 2002-05-16 2004-03-10 Евгений Ильич Зарайский (RU) Способ лечения диабетической ретинопатии
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
RU2014126070A (ru) 2011-12-01 2016-01-27 Глэксо Груп Лимитед Способы лечения и предотвращения глазных заболеваний
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
SG11201909245PA (en) 2017-04-05 2019-11-28 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists
WO2013149986A1 (en) * 2012-04-03 2013-10-10 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
WO2013149987A1 (en) * 2012-04-04 2013-10-10 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising ccr3 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nagineni, CN, et al., "Inflammatory Cytokines Induce Expression of Chemokines by Human Retinal Cells: Role in Chemokine Receptor Mediated Age-related Macular Degeneration", Aging and Disease, 2015, vol. 6, no. 6, pages 444-455, XP055479864 *

Also Published As

Publication number Publication date
US11951102B2 (en) 2024-04-09
EP4245295A3 (en) 2023-11-01
MY199462A (en) 2023-10-30
ES3046717T3 (en) 2025-12-02
IL269743A (en) 2019-11-28
TW201841636A (zh) 2018-12-01
JP2020513004A (ja) 2020-04-30
US20240024305A1 (en) 2024-01-25
EP3606521B1 (en) 2023-04-19
EP4245295A2 (en) 2023-09-20
NZ757769A (en) 2025-10-31
JP7179755B2 (ja) 2022-11-29
KR20190131121A (ko) 2019-11-25
KR102658724B1 (ko) 2024-04-18
MX394915B (es) 2025-03-24
BR112019020430A2 (pt) 2021-03-30
EA201992356A1 (ru) 2020-03-23
CO2019012336A2 (es) 2020-04-01
US20210106577A1 (en) 2021-04-15
CN110650740A (zh) 2020-01-03
MX2019012012A (es) 2019-12-11
UA125658C2 (uk) 2022-05-11
IL269743B (en) 2022-09-01
US11590118B2 (en) 2023-02-28
AU2024204133B2 (en) 2026-03-26
ES2950453T3 (es) 2023-10-10
EP3606521A1 (en) 2020-02-12
AU2024204133A1 (en) 2024-07-04
CL2019002839A1 (es) 2020-06-05
WO2018187473A1 (en) 2018-10-11
SG11201909207VA (en) 2019-11-28
CA3058654A1 (en) 2018-10-11
AU2018248425A1 (en) 2019-10-31
EP4245295B1 (en) 2025-08-06

Similar Documents

Publication Publication Date Title
AU2024204133B2 (en) Methods and Compositions for Treating Retina-Associated Disease Using CCR3-Inhibitors
TWI530494B (zh) 用於治療與類澱粉或類澱粉樣蛋白質相關疾病之新穎化合物
CN107847499A (zh) 治疗神经退行性疾病的方法
IL269787A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
TWI833535B (zh) 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥
CN115768433A (zh) 含有司培前列素的医药制剂
CN111343983A (zh) 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
HK40012545A (en) Methods and compositions for treating retina-associated disease using ccr3-inhibitors
WO2016006621A1 (ja) Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
CA3111433C (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK40102807A (en) Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40102807B (en) Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
CN111491636A (zh) 奥米帕格的组合
HK40029829A (en) Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 18 APR 2022

FGA Letters patent sealed or granted (standard patent)